Trial Profile
A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Adenocarcinoma; Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Oct 2019 Status changed from active, no longer recruiting to completed according to results published in the Gynecologic Oncology.
- 15 Oct 2019 Results published in the Gynecologic Oncology
- 10 Aug 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.